Media stories about REGENXBIO (NASDAQ:RGNX) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. REGENXBIO earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.5422977473694 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
Get REGENXBIO alerts:
Quant Scorecard Under Review For REGENXBIO Inc. (NasdaqGS:RGNX) (derbynewsjournal.com) Regenxbio Inc (RGNX) AroonUp Technicals Showing Momentum Building (parkcitycaller.com) Showing Signs of Life? Stock Update on REGENXBIO Inc. (NASDAQ:RGNX) (parkcitycaller.com) Relative Strength Index (RSI 14) to Watch Mueller Water Products, Inc. (NYSE:MWA), REGENXBIO Inc. (NASDAQ … (stocksnewspoint.com) Are You Looking For Opportunity on Stock? REGENXBIO Inc. (RGNX) (nysestocks.review)
A number of research firms have weighed in on RGNX. TheStreet upgraded REGENXBIO from a “d+” rating to a “c” rating in a research note on Friday, May 11th. ValuEngine upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. Raymond James set a $45.00 price objective on REGENXBIO and gave the company a “buy” rating in a research note on Tuesday, May 8th. Barclays reiterated an “overweight” rating and set a $48.00 price objective (up previously from $38.00) on shares of REGENXBIO in a research note on Wednesday, May 9th. Finally, BidaskClub upgraded REGENXBIO from a “hold” rating to a “buy” rating in a research note on Friday, April 20th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $43.25.
NASDAQ RGNX opened at $48.70 on Monday. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -19.88, a P/E/G ratio of 26.05 and a beta of -1.23. REGENXBIO has a fifty-two week low of $16.30 and a fifty-two week high of $51.20.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, May 8th. The biotechnology company reported $3.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.00 by $2.04. REGENXBIO had a return on equity of 23.27% and a net margin of 37.28%. The firm had revenue of $132.39 million during the quarter, compared to analyst estimates of $80.00 million. equities research analysts expect that REGENXBIO will post 0.61 earnings per share for the current fiscal year.
In related news, CFO Vittal Vasista sold 5,000 shares of REGENXBIO stock in a transaction dated Monday, March 26th. The stock was sold at an average price of $30.00, for a total value of $150,000.00. Following the completion of the transaction, the chief financial officer now owns 157,283 shares in the company, valued at approximately $4,718,490. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Kenneth T. Mills sold 10,000 shares of REGENXBIO stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $26.56, for a total value of $265,600.00. Following the completion of the transaction, the insider now owns 238,530 shares of the company’s stock, valued at approximately $6,335,356.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 107,500 shares of company stock valued at $3,975,600. 16.90% of the stock is owned by company insiders.
REGENXBIO Company Profile
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.